Overman, M. J., Yothers, G., Puhalla, S. L., Sanoff, H. K., Cohen, D. J., Guthrie, K. A., Ganz, P. A., Kopetz, S., Lucas, P. C., Blanke, C. D., Jacobs, S. A., Hong, T. S., Wolmark, N., Hochster, H. S., George, T. J., Lima, C. M. S. P. R. (2025). Colorectal cancer metastatic dMMR immunotherapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer 9NRG-GI004/SWOG-S1610).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.tps311